Showing 1821-1830 of 10536 results for "".
Biosimilar Recommended; Saunders to Head New Pfizer/Allergan Organization
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-biosimilar-recommended-saunders-to-head-new-pfizer-allergan-organization/18825/An FDA committee has recommended Pfizer's Inflectra, biosimilar to infliximab, developed by Celltrion. Sunbelt Melanoma Trial finds no benefit for IFN in Phase III melanoma. Pfizer/Allergan provides details on structure of new organization and announces leadership, including President and COO BrentA Matter of Scales
https://practicaldermatology.com/series/diversity-and-equity-in-dermatology/a-matter-of-scales/19917/The "classic" descriptions of skin diseases and the scales used to assess disease severity often are based on white skin. But skin diseases can appear differently across skin types. The panelists discuss the need for updated tools, including the need to rethink skin type scales.DermWireTV: Sanofi Genzyme & Regeneron Global AD Report; Hydroquinone; Pfizer NDA; VCS
https://practicaldermatology.com/topics/practice-management/dermwiretv-sanofi-genzyme-regeneron-global-ad-report-hydroquinone-pfizer-nda-vcs/19868/The “Improving Quality of Care in AD” report, commissioned and funded by Sanofi Genzyme & Regeneron and completed by KPMG, debuts at the annual meeting of the EADV. Changes to FDA regulations implemented as part of the CARES Act limit access to hydroquinone. This year’s Virtual Vegas Cosmetic SuGalderma's Future, Allergan's Bonti Buy, and Sebacia Clearance
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-galderma-s-future-allergan-s-bonti-buy-and-sebacia-clearance--xgheloga/18233/Nestle's Board says it has come to the conclusion that the future growth opportunities of Nestlé Skin Health lie increasingly outside the Group's strategic scope and expects a review of strategic options for Nestlé Skin Health to be complete by mid-2019. Allergan is acquiring Bonti for 195 million dABD Eyes Mohs Certification, Sun's Ilumya Approved, FUE Update
https://practicaldermatology.com/topics/psoriasis/dermwiretv-abd-eyes-mohs-certification-sun-s-ilumya-approved-fue-update/18319/The American Board of Dermatology has notified the American Board of Medical Specialties it wants to offer a subspecialty certificate in Micrographic Dermatologic Surgery. Dermatologists react. Ilumya or tildrakizumab from Sun Pharma is approved for moderate to severe psoriasis. Medicine the MusicalAAD & Week of Science, ADCETRIS CTCL Data, SILIQ Pricing
https://practicaldermatology.com/topics/skin-cancer-photoprotection/-dermwiretv-aad-week-of-science-adcetris-ctcl-data-siliq-pricing/18482/It's the Week of Science. The American Academy of Dermatology has joined a large group of other medical group in supporting the March for Science and its principles. Adults with hyperpigmentation tend to use sunscreen, but they are less likely to use other UV avoidance strategies, new research in JATo Be Shorr: Use Call Tracking Numbers to Measure Your Marketing ROI
https://practicaldermatology.com/topics/practice-management/to-be-shorr-use-call-tracking-numbers-to-measure-your-marketing-roi/18604/Tracking ROI on your marketing initiatives is an important but sometimes challenging undertaking. In this edition of "To Be Shorr," Mara Shorr, BS, CAC II-V shares tips for easily tracking your investments, including the use of call tracking numbers.Clinical Conversations: Discover Dr J Scott Boswell’s Perspective on Redefining PN and AD Through a Neuroimmune Lens
https://practicaldermatology.com/programs/nemluvio-peer-network/clinical-conversations-discover-dr-j-scott-boswells-perspective-on-redefining-pn-and-ad-through-a-neuroimmune-lens/56421/In this Clinical Conversations newsletter, Dr Scott Boswell shares how reframing prurigo nodularis (PN) and atopic dermatitis (AD) as neuroimmune-driven conditions has shaped his clinical philosophy. He shares his 3‑step approach to patient communication, highlights real‑world treatment journeys inDermatologists Push Back on Wall Street Journal Characterization
https://practicaldermatology.com/issues/january-february-2025/dermatologists-push-back-on-wsj-characterization/32900/Four-day workweeks, double the salary of some colleagues and no emails at night—those were the reasons a Wall Street Journal article concluded that medical residency applications for dermatology slots are up 50% over the past 5 years. Practical Dermatology reached out to dermatologists to get theirDermWire TV: Positive Data on UCB's Bimekizumab in HS patients; CSF takes Nashville by Storm; Rocatinlimab Performs Well in AD
https://practicaldermatology.com/topics/psoriasis/dermwire-tv-positive-data-on-ucbs-bimekizumab-hs-patients-csf-takes-nashville-by-storm-rocatinlimab-performs-well-in-ad/20159/Bimekizumab performs well in Hidradenitis Suppurativa patients, Cosmetic Surgery Forum takes Nashville by storm, and Rocatinlimab—a novel monoclonal antibody therapy—shows promise in atopic dermatitis are the stories topping the news in this episode of DermWireTV.